Due to disbalance between the production and the release rates of BM cells in vivo, the Lyve-1+/Pdpn+ fraction of lymphatic progenitors accounted only for 6% of total cells (Fig 6B), which is significantly lower than in an in vitro assay shielded from tumor-induced mobilization. Here, LYVE1 is linked to neoplasm.